OBJECTIVE: The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). This report provides detailed results on the metabolic effects of pioglitazone and the trial's prespecified secondary aim of diabetes prevention. RESEARCH DESIGN AND METHODS: A total of 3,876 patients with recent ischemic stroke or TIA, no history of diabetes, fasting plasma glucose (FPG) <126 mg/dL, and insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR) score >3.0 were randomly assigned to pioglitazone or placebo. Surveillance for diabetes onset during the trial was accomplished by periodic interviews and annual FPG testing. RESULTS: At baseline, the mean FPG, HbA1c, insulin, and HOMA-IR were 98.2 mg/dL (5.46 mmol/L), 5.8% (40 mmol/mol), 22.4 μIU/mL, and 5.4, respectively. After 1 year, mean HOMA-IR and FPG decreased to 4.1 and 95.1 mg/dL (5.28 mmol/L) in the pioglitazone group and rose to 5.7 and 99.7 mg/dL (5.54 mmol/L), in the placebo group (all P < 0.0001). Over a median follow-up of 4.8 years, diabetes developed in 73 (3.8%) participants assigned to pioglitazone compared with 149 (7.7%) assigned to placebo (hazard ratio [HR] 0.48 [95% CI 0.33-0.69]; P < 0.0001). This effect was predominately driven by those with initial impaired fasting glucose (FPG >100 mg/dL [5.6 mmol/L]; HR 0.41 [95% CI 0.30-0.57]) or elevated HbA1c (>5.7% [39 mmol/mol]; HR 0.46 [0.34-0.62]). CONCLUSIONS: Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.
RCT Entities:
OBJECTIVE: The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). This report provides detailed results on the metabolic effects of pioglitazone and the trial's prespecified secondary aim of diabetes prevention. RESEARCH DESIGN AND METHODS: A total of 3,876 patients with recent ischemic stroke or TIA, no history of diabetes, fasting plasma glucose (FPG) <126 mg/dL, and insulin resistance by homeostasis model assessment of insulin resistance (HOMA-IR) score >3.0 were randomly assigned to pioglitazone or placebo. Surveillance for diabetes onset during the trial was accomplished by periodic interviews and annual FPG testing. RESULTS: At baseline, the mean FPG, HbA1c, insulin, and HOMA-IR were 98.2 mg/dL (5.46 mmol/L), 5.8% (40 mmol/mol), 22.4 μIU/mL, and 5.4, respectively. After 1 year, mean HOMA-IR and FPG decreased to 4.1 and 95.1 mg/dL (5.28 mmol/L) in the pioglitazone group and rose to 5.7 and 99.7 mg/dL (5.54 mmol/L), in the placebo group (all P < 0.0001). Over a median follow-up of 4.8 years, diabetes developed in 73 (3.8%) participants assigned to pioglitazone compared with 149 (7.7%) assigned to placebo (hazard ratio [HR] 0.48 [95% CI 0.33-0.69]; P < 0.0001). This effect was predominately driven by those with initial impaired fasting glucose (FPG >100 mg/dL [5.6 mmol/L]; HR 0.41 [95% CI 0.30-0.57]) or elevated HbA1c (>5.7% [39 mmol/mol]; HR 0.46 [0.34-0.62]). CONCLUSIONS: Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone is the first medication shown to prevent both progression to diabetes and major cardiovascular events as prespecified outcomes in a single trial.
Authors: Ralph A DeFronzo; Devjit Tripathy; Dawn C Schwenke; MaryAnn Banerji; George A Bray; Thomas A Buchanan; Stephen C Clement; Robert R Henry; Howard N Hodis; Abbas E Kitabchi; Wendy J Mack; Sunder Mudaliar; Robert E Ratner; Ken Williams; Frankie B Stentz; Nicolas Musi; Peter D Reaven Journal: N Engl J Med Date: 2011-03-24 Impact factor: 91.245
Authors: James D Lewis; Laurel A Habel; Charles P Quesenberry; Brian L Strom; Tiffany Peng; Monique M Hedderson; Samantha F Ehrlich; Ronac Mamtani; Warren Bilker; David J Vaughn; Lisa Nessel; Stephen K Van Den Eeden; Assiamira Ferrara Journal: JAMA Date: 2015-07-21 Impact factor: 56.272
Authors: Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu Journal: JAMA Date: 2008-03-31 Impact factor: 56.272
Authors: Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder Journal: N Engl J Med Date: 2016-02-17 Impact factor: 91.245
Authors: F Strollo; C Macchi; I Eberini; M A Masini; M Botta; G Vassilieva; I Nichiporuk; M Monici; D Santucci; F Celotti; P Magni; M Ruscica Journal: J Endocrinol Invest Date: 2018-03-12 Impact factor: 4.256
Authors: Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke Journal: Nat Rev Gastroenterol Hepatol Date: 2020-10-22 Impact factor: 46.802
Authors: Medha N Munshi; Graydon S Meneilly; Leocadio Rodríguez-Mañas; Kelly L Close; Paul R Conlin; Tali Cukierman-Yaffe; Angus Forbes; Om P Ganda; C Ronald Kahn; Elbert Huang; Lori M Laffel; Christine G Lee; Sei Lee; David M Nathan; Naushira Pandya; Richard Pratley; Robert Gabbay; Alan J Sinclair Journal: Lancet Diabetes Endocrinol Date: 2020-10 Impact factor: 32.069